Inibidores do SGLT-2

Funding Information: José Silva-Cardoso has received speaker and consultant fees, advisory board participation fees, or investigational grants from Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servi...

Full description

Bibliographic Details
Main Author: Silva-Cardoso, José (author)
Other Authors: Andrade, Aurora (author), Brito, Dulce (author), Ferreira, Jorge (author), Fonseca, Cândida (author), Peres, Marisa (author), Franco, Fátima (author), Moura, Brenda (author)
Format: review
Language:por
Published: 2021
Subjects:
Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
Online Access:http://hdl.handle.net/10362/120537
Country:Portugal
Oai:oai:run.unl.pt:10362/120537

Internet

http://hdl.handle.net/10362/120537

Similar Items